* Clearside Biomedical Inc CLSD.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter , higher than the
same quarter last year, when the company reported EPS of -15
cents. The mean expectation of seven analysts for the quarter
was for a loss of 12 cents per share. Wall Street expected
results to range from -16 cents to -9 cents per share.
* Revenue rose 20.8% to $1.04 million from a year ago;
analysts
expected $122.86 thousand.
* Clearside Biomedical Inc's reported EPS for the quarter
was a
loss of 10 cents.
* The company reported a quarterly loss of $7.69 million.
* Clearside Biomedical Inc shares had fallen by 12.6% this
quarter and lost 5.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Clearside
Biomedical Inc is $6.00
This summary was machine generated from LSEG data November 13 at
02:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.12 -0.10 Beat
Jun. 30 2024 -0.13 -0.10 Beat
Mar. 31 2024 -0.15
Dec. 31 2023 -0.09 -0.08 Beat